NewsJAMATuesday, March 24, 2026 · March 24, 2026
Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough: The CORAL Randomized Clinical Trial.
WHY IT MATTERS
Recent peer-reviewed research on Idiopathic pulmonary fibrosis that may be relevant for patients and caregivers.
For patients with idiopathic pulmonary fibrosis (IPF), cough impairs quality of life; effective treatments for IPF-associated cough are needed. To determine if nalbuphine extended release (ER), a κ opioid receptor agonist and μ-opioid receptor antagonist, decreases cough compared with pl...
Related conditions
Related news
Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.…